An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immunemediated thrombotic thrombocytopenic purpura
This study is investigating a new approach to treating a rare and serious blood condition called immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP). Currently, a common treatment for iTTP is therapeutic plasma exchange (TPE), which involves filtering the patient's blood. This study aims to see if a medication called Cablivi, when given alongside standard immune-suppressing treatments, can help adult patients with iTTP go into remission and recover without needing TPE. Researchers will be closely monitoring how well patients respond to the treatment and if there are any side effects. This is a Phase III study, meaning it's a later stage of research designed to confirm if the new treatment is effective and safe.
En un coup d'œil
De quoi parle cette étude ?
This study is about finding a new way to treat a rare but serious blood disease called immune-mediated Thrombotic Thrombocytopenic Purpura, or iTTP for short. In iTTP, your body mistakenly attacks itself, leading to tiny blood clots forming in small blood vessels. This can cause problems with your blood, kidneys, brain, and heart.
Currently, a common treatment for iTTP is called therapeutic plasma exchange, often shortened to TPE. This is a procedure where a machine filters your blood to remove harmful substances. While TPE is effective, it can be quite intensive and involves frequent hospital visits. This study is exploring if a new medicine called Cablivi, given along with other medicines that calm down your immune system, can help adult patients with iTTP get better and go into remission without needing the TPE procedure.
The main goal of the study is to see how many patients get better and into remission without needing TPE. The researchers will also be carefully watching for any side effects and how quickly people respond to the new treatment. This is an important step in potentially offering patients with iTTP a different, possibly less intensive, treatment option in the future.
Points clés
- Tests a new medicine (Cablivi) for iTTP.
- Aims to help patients get better without plasma exchange.
- Combines Cablivi with other immune-suppressing treatments.
- Involves regular hospital visits and monitoring.
- Open to adults 18 years and older with iTTP.
- Vous pouvez arrêter de participer à tout moment.
Qui peut être éligible ?
To join this study, you must be an adult, 18 years or older, and have been diagnosed with immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP).
The study is open to both men and women with iTTP. There will be other specific medical checks to make sure the treatment is safe for you and that the study results are clear. These will involve looking at your overall health and any other medications you might be taking.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Have you been diagnosed with immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)?
- Are you able to attend regular hospital appointments for check-ups and treatment?
- Are you generally well enough to participate in a medical study in addition to your iTTP diagnosis?
En quoi consiste la participation ?
If you decide to take part in this study, you would receive the study medication, Cablivi, as an injection, along with other treatments to suppress your immune system. You would have regular appointments at the hospital or clinic for check-ups, blood tests, and to make sure the treatment is working well and safely. The study would involve close monitoring, especially in the beginning. The main part of the treatment will last for about 84 days (around 12 weeks), but you would be followed up for a longer period, up to 168 days (about 24 weeks), to see how you are doing after treatment.
Risques et avantages potentiels
Locations (9)
- —Non vérifiéPays-Bas
- —Non vérifiéTchéquie
- —Non vérifiéEspagne
- —Non vérifiéAutriche
- —Non vérifiéItalie
- —Non vérifiéAllemagne
- —Non vérifiéFrance
- —Non vérifiéBelgique
- —Non vérifiéGrèce
Questions fréquentes
What is iTTP?
iTTP is a rare blood disorder where your immune system mistakenly attacks healthy cells, causing tiny blood clots to form and leading to problems with your blood and organs.
What is plasma exchange?
Plasma exchange is a procedure that cleans your blood by removing harmful substances, often used to treat iTTP. This study is looking at ways to avoid needing it.
What is Cablivi?
Cablivi is a medicine being tested in this study. It's given as an injection and aims to stop the blood clots from forming in iTTP.
Will I still get other treatments if I join?
Yes, you would receive Cablivi along with other standard treatments that help calm your immune system.
How long will this study last for me?
The main treatment phase will be about 12 weeks, followed by a monitoring period, making the total study time up to 24 weeks.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.